Robert D. Allen III - 15 Aug 2025 Form 4 Insider Report for Invivyd, Inc. (IVVD)

Role
Chief Scientific Officer
Signature
/s/ Jill Andersen attorney-in-fact for Robert D. Allen III
Issuer symbol
IVVD
Transactions as of
15 Aug 2025
Net transactions value
-$27,573
Form type
4
Filing time
19 Aug 2025, 21:20:20 UTC
Previous filing
19 Feb 2025
Next filing
30 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Allen Robert D. III Chief Scientific Officer C/O INVIVYD, INC., 1601 TRAPELO ROAD, SUITE 178, WALTHAM /s/ Jill Andersen attorney-in-fact for Robert D. Allen III 19 Aug 2025 0001972424

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IVVD Common Stock Options Exercise +99,000 99,000 15 Aug 2025 Direct F1
transaction IVVD Common Stock Sale $12,037 -18,512 -19% $0.6502 80,488 18 Aug 2025 Direct F2, F3
transaction IVVD Common Stock Sale $15,536 -27,420 -34% $0.5666 53,068 19 Aug 2025 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IVVD Restricted Stock Units Options Exercise $0 -99,000 -33% $0.000000 201,000 15 Aug 2025 Common Stock 99,000 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company").
F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.5801 to $0.7134, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.5524 to $0.6040, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
F5 This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date.

Remarks:

Exhibit 24.1: Power of Attorney